CytoDyn Completes Non-dilutive $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share without Warrants Jul 29, 2020 6:56pm EDT
CytoDyn to Hold Conference Call on July 30 to Provide Updates on its Two COVID-19 Trials Jul 27, 2020 6:00am EDT
CytoDyn’s CEO Dr. Pourhassan to Appear on DrBeen Webcast Tomorrow July 18, 2020 Jul 17, 2020 5:31pm EDT
Update on HIV-BLA-PDUFA: FDA requested more information to complete a substantive review. No additional trials required. CytoDyn plans to submit the requested information and will ask for a Type A meeting with the FDA per the agency’s suggestion Jul 13, 2020 6:00am EDT
CytoDyn to Present at Wall Street Reporter’s Livestream Event on July 9, 2020 at 1:30 pm ET / 10:30 am PT Jul 08, 2020 5:34pm EDT
